Cargando…
Research progress in clinical trials of stem cell therapy for stroke and neurodegenerative diseases
The incidence of stroke and neurodegenerative diseases is gradually increasing in modern society, but there is still no treatment that is effective enough. Stem cells are cells that can reproduce (self‐renew) and differentiate into the body, which have shown significance in basic research, while doc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529019/ https://www.ncbi.nlm.nih.gov/pubmed/37786546 http://dx.doi.org/10.1002/ibra.12095 |
_version_ | 1785111336970092544 |
---|---|
author | Yan, Shan‐Shan Campos de Souza, Senio Xie, Zhen‐Dong Bao, Yong‐Xin |
author_facet | Yan, Shan‐Shan Campos de Souza, Senio Xie, Zhen‐Dong Bao, Yong‐Xin |
author_sort | Yan, Shan‐Shan |
collection | PubMed |
description | The incidence of stroke and neurodegenerative diseases is gradually increasing in modern society, but there is still no treatment that is effective enough. Stem cells are cells that can reproduce (self‐renew) and differentiate into the body, which have shown significance in basic research, while doctors have also taken them into clinical trials to determine their efficacy and safety. Existing clinical trials mainly include middle‐aged and elderly patients with stroke or Parkinson's disease (mostly 40–80 years old), mainly involving injection of mesenchymal stem cells and bone marrow mesenchymal stem cells through the veins and the putamen, with a dosage of mostly 10(6)–10(8) cells. The neural and motor functions of the patients were restored after stem cell therapy, and the safety was found to be good during the follow‐up period of 3 months to 5 years. Here, we review all clinical trials and the latest advances in stroke, Alzheimer's disease, and Parkinson's disease, with the hope that stem cell therapy will be used in the clinic in the future to achieve effective treatment rates and benefit patients. |
format | Online Article Text |
id | pubmed-10529019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105290192023-10-02 Research progress in clinical trials of stem cell therapy for stroke and neurodegenerative diseases Yan, Shan‐Shan Campos de Souza, Senio Xie, Zhen‐Dong Bao, Yong‐Xin Ibrain Reviews The incidence of stroke and neurodegenerative diseases is gradually increasing in modern society, but there is still no treatment that is effective enough. Stem cells are cells that can reproduce (self‐renew) and differentiate into the body, which have shown significance in basic research, while doctors have also taken them into clinical trials to determine their efficacy and safety. Existing clinical trials mainly include middle‐aged and elderly patients with stroke or Parkinson's disease (mostly 40–80 years old), mainly involving injection of mesenchymal stem cells and bone marrow mesenchymal stem cells through the veins and the putamen, with a dosage of mostly 10(6)–10(8) cells. The neural and motor functions of the patients were restored after stem cell therapy, and the safety was found to be good during the follow‐up period of 3 months to 5 years. Here, we review all clinical trials and the latest advances in stroke, Alzheimer's disease, and Parkinson's disease, with the hope that stem cell therapy will be used in the clinic in the future to achieve effective treatment rates and benefit patients. John Wiley and Sons Inc. 2023-03-05 /pmc/articles/PMC10529019/ /pubmed/37786546 http://dx.doi.org/10.1002/ibra.12095 Text en © 2023 The Authors. Ibrain published by Affiliated Hospital of Zunyi Medical University and Wiley‐VCH GmbH. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Yan, Shan‐Shan Campos de Souza, Senio Xie, Zhen‐Dong Bao, Yong‐Xin Research progress in clinical trials of stem cell therapy for stroke and neurodegenerative diseases |
title | Research progress in clinical trials of stem cell therapy for stroke and neurodegenerative diseases |
title_full | Research progress in clinical trials of stem cell therapy for stroke and neurodegenerative diseases |
title_fullStr | Research progress in clinical trials of stem cell therapy for stroke and neurodegenerative diseases |
title_full_unstemmed | Research progress in clinical trials of stem cell therapy for stroke and neurodegenerative diseases |
title_short | Research progress in clinical trials of stem cell therapy for stroke and neurodegenerative diseases |
title_sort | research progress in clinical trials of stem cell therapy for stroke and neurodegenerative diseases |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529019/ https://www.ncbi.nlm.nih.gov/pubmed/37786546 http://dx.doi.org/10.1002/ibra.12095 |
work_keys_str_mv | AT yanshanshan researchprogressinclinicaltrialsofstemcelltherapyforstrokeandneurodegenerativediseases AT camposdesouzasenio researchprogressinclinicaltrialsofstemcelltherapyforstrokeandneurodegenerativediseases AT xiezhendong researchprogressinclinicaltrialsofstemcelltherapyforstrokeandneurodegenerativediseases AT baoyongxin researchprogressinclinicaltrialsofstemcelltherapyforstrokeandneurodegenerativediseases |